These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36856671)

  • 21. Nanovaccines against Animal Pathogens: The Latest Findings.
    Celis-Giraldo CT; López-Abán J; Muro A; Patarroyo MA; Manzano-Román R
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
    Engeroff P; Bachmann MF
    Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liposome Formulations as Adjuvants for Vaccines.
    Rao M; Peachman KK; Alving CR
    Curr Top Microbiol Immunol; 2021; 433():1-28. PubMed ID: 33165871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview on liposomal delivery and adjuvant development for leishmaniosis vaccines.
    Soosaraei M; Hezarjaribi HZ; Fakhar M; Akhtari J; Emameh RZ
    Ann Parasitol; 2021; 67(3):367-386. PubMed ID: 34953114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.
    Perrie Y; Kastner E; Kaur R; Wilkinson A; Ingham AJ
    Hum Vaccin Immunother; 2013 Jun; 9(6):1374-81. PubMed ID: 23584249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticle-based vaccine development and evaluation against viral infections in pigs.
    Dhakal S; Renukaradhya GJ
    Vet Res; 2019 Nov; 50(1):90. PubMed ID: 31694705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmid-DNA lipid and polymeric nanovaccines: a new strategic in vaccines development.
    Tejeda-Mansir A; García-Rendón A; Guerrero-Germán P
    Biotechnol Genet Eng Rev; 2019 Apr; 35(1):46-68. PubMed ID: 30587085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of nano-carriers for
    Askarizadeh A; Badiee A; Khamesipour A
    Expert Opin Drug Deliv; 2020 Feb; 17(2):167-187. PubMed ID: 31914821
    [No Abstract]   [Full Text] [Related]  

  • 29. Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.
    Grego EA; Siddoway AC; Uz M; Liu L; Christiansen JC; Ross KA; Kelly SM; Mallapragada SK; Wannemuehler MJ; Narasimhan B
    Curr Top Microbiol Immunol; 2021; 433():29-76. PubMed ID: 33165869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Licensed liposomal vaccines and adjuvants in the antigen delivery system.
    Krasnopolsky Y; Pylypenko D
    BioTechnologia (Pozn); 2022; 103(4):409-423. PubMed ID: 36685697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators.
    Tandrup Schmidt S; Foged C; Korsholm KS; Rades T; Christensen D
    Pharmaceutics; 2016 Mar; 8(1):. PubMed ID: 26978390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomal adjuvant development for leishmaniasis vaccines.
    Askarizadeh A; Jaafari MR; Khamesipour A; Badiee A
    Ther Adv Vaccines; 2017 Aug; 5(4-5):85-101. PubMed ID: 29201374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant and antigen delivery properties of virosomes.
    Glück R; Burri KG; Metcalfe I
    Curr Drug Deliv; 2005 Oct; 2(4):395-400. PubMed ID: 16305442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The new era of vaccines: the "nanovaccinology".
    Facciolà A; Visalli G; Laganà P; La Fauci V; Squeri R; Pellicanò GF; Nunnari G; Trovato M; Di Pietro A
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):7163-7182. PubMed ID: 31486519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymeric nanoparticle-based nanovaccines for cancer immunotherapy.
    Zhang Y; Chen J; Shi L; Ma F
    Mater Horiz; 2023 Feb; 10(2):361-392. PubMed ID: 36541078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging Trends in Lipid-Based Vaccine Delivery: A Special Focus on Developmental Strategies, Fabrication Methods, and Applications.
    Karunakaran B; Gupta R; Patel P; Salave S; Sharma A; Desai D; Benival D; Kommineni N
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
    Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
    Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced efficacy of immersion vaccination in tilapia against columnaris disease by chitosan-coated "pathogen-like" mucoadhesive nanovaccines.
    Kitiyodom S; Yata T; Yostawornkul J; Kaewmalun S; Nittayasut N; Suktham K; Surassmo S; Namdee K; Rodkhum C; Pirarat N
    Fish Shellfish Immunol; 2019 Dec; 95():213-219. PubMed ID: 31585248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virus-like particle vaccines and adjuvants: the HPV paradigm.
    Buonaguro FM; Tornesello ML; Buonaguro L
    Expert Rev Vaccines; 2009 Oct; 8(10):1379-98. PubMed ID: 19803760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.